Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of in-vitro diagnostic products in China and internationally. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; human serum albumin; human prothrombin complex and human coagulation factor VIII; and vaccine for r...
Beijing Bohui Innovation Biotechnology Group reported revenue of 824.58 million CNY for fiscal year 2025, down 3.2% from fiscal year 2024, and net income of -91.92 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 189.86 million CNY, down 5.8% from a year before. Its largest business segment, Biological Products, brought in 68% of segment revenue in fiscal year 2024; Northern China was the largest region with 22%.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.